Molecular Cancer Therapeutics Funding
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rosato, R. R.
Right arrow Articles by Grant, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rosato, R. R.
Right arrow Articles by Grant, S.
Vol. 1, 253-266, February 2002     Molecular Cancer Therapeutics
© 2002 American Association for Cancer Research

The Cyclin-dependent Kinase Inhibitor Flavopiridol Disrupts Sodium Butyrate-induced p21WAF1/CIP1 Expression and Maturation while Reciprocally Potentiating Apoptosis in Human Leukemia Cells 1

Roberto R. Rosato, Jorge A. Almenara, Leanne Cartee, Vicki Betts, Srikumar P. Chellappan and Steven Grant2

Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond Virginia, 23298 [R. R. R., J. A. A., L. C., S. G.], and the Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York 10021 [V. B., S. P. C.]

Interactions between the cyclin-dependent kinase inhibitor flavopiridol (FP) and the histone deacetylase inhibitor sodium butyrate (SB) have been examined in human leukemia cells (U937) in relation to differentiation and apoptosis. Whereas 1 mm of SB or 100 nm of FP minimally induced apoptosis (4% and 10%, respectively) at 24 h, simultaneous exposure of U937 cells to these agents dramatically increased cell death (e.g., ~60%), reflected by both morphological and Annexin/propidium iodide-staining features, procaspase 3 activation, and poly(ADP-ribose) polymerase cleavage. Similar interactions were observed in human promyelocytic (HL-60), B-lymphoblastic (Raji), and T-lymphoblastic (Jurkat) leukemia cells. Coadministration of FP opposed SB-mediated accumulation of cells in G0G1 and differentiation, reflected by reduced CD11b expression, but instead dramatically increased procaspase-3, procaspase-8, Bid, and poly(ADP-ribose) polymerase cleavage, as well as mitochondrial damage (e.g., loss of mitochondrial membrane potential and cytochrome c release). FP also blocked SB-related p21WAF1-CIP1 induction through a caspase-independent mechanism and triggered the caspase-mediated cleavage of p27KIP1 and retinoblastoma protein. The latter event was accompanied by a marked reduction in retinoblastoma protein/E2F1 complex formation. However, FP did not modify the extent of SB-associated acetylation of histones H3 and H4. Treatment of cells with FP/SB also resulted in the caspase-mediated cleavage of Bcl-2 and caspase-independent down-regulation of Mcl-1. Levels of cyclins A, D1, and E, and X-linked inhibitor of apoptosis also declined in SB/FP-treated cells. Finally, FP/SB coexposure potently induced apoptosis in two primary acute myelogenous leukemia samples. Together, these findings demonstrate that FP, when combined with SB, induces multiple perturbations in cell cycle and apoptosis regulatory proteins, which oppose leukemic cell differentiation but instead promote mitochondrial damage and apoptosis.




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, S. C. Maggio, S. Coe, P. Atadja, P. Dent, and S. Grant
Role of histone deacetylase inhibitor-induced reactive oxygen species and DNA damage in LAQ-824/fludarabine antileukemic interactions
Mol. Cancer Ther., October 1, 2008; 7(10): 3285 - 3297.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S.-R. A. Hussain, D. M. Lucas, A. J. Johnson, T. S. Lin, A. P. Bakaletz, V. X. Dang, S. Viatchenko-Karpinski, A. S. Ruppert, J. C. Byrd, P. Kuppusamy, et al.
Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium
Blood, March 15, 2008; 111(6): 3190 - 3199.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
P. Brest, M. Gustafsson, A.-K. Mossberg, L. Gustafsson, C. Duringer, A. Hamiche, and C. Svanborg
Histone Deacetylase Inhibitors Promote the Tumoricidal Effect of HAMLET
Cancer Res., December 1, 2007; 67(23): 11327 - 11334.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. R. Rosato, J. A. Almenara, S. Coe, and S. Grant
The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation
Cancer Res., October 1, 2007; 67(19): 9490 - 9500.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, S. S. Kolla, S. C. Maggio, S. Coe, M. S. Gimenez, P. Dent, and S. Grant
Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions
Mol. Cancer Ther., February 1, 2007; 6(2): 692 - 702.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
N. Gao, L. Kramer, M. Rahmani, P. Dent, and S. Grant
The Three-Substituted Indolinone Cyclin-Dependent Kinase 2 Inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) Kills Human Leukemia Cells via Down-Regulation of Mcl-1 through a Transcriptional Mechanism
Mol. Pharmacol., August 1, 2006; 70(2): 645 - 655.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Nyakern, A. Cappellini, I. Mantovani, and A. M. Martelli
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways.
Mol. Cancer Ther., June 1, 2006; 5(6): 1559 - 1570.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, S. C. Maggio, P. Atadja, R. Craig, J. Vrana, P. Dent, and S. Grant
Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells
Mol. Cancer Ther., November 1, 2005; 4(11): 1772 - 1785.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
K. N. Bhalla
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
J. Clin. Oncol., June 10, 2005; 23(17): 3971 - 3993.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
R Rust, G Harms, T Blokzijl, M Boot, A Diepstra, J Kluiver, L Visser, S-C Peh, M Lim, W A Kamps, et al.
High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma
J. Clin. Pathol., May 1, 2005; 58(5): 520 - 524.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. A. Strait, C. T. Warnick, C. D. Ford, B. Dabbas, E. H. Hammond, and S. J. Ilstrup
Histone deacetylase inhibitors induce G2-checkpoint arrest and apoptosis in cisplatinum-resistant ovarian cancer cells associated with overexpression of the Bcl-2-related protein Bad
Mol. Cancer Ther., April 1, 2005; 4(4): 603 - 611.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Rahmani, E. Reese, Y. Dai, C. Bauer, S. G. Payne, P. Dent, S. Spiegel, and S. Grant
Coadministration of Histone Deacetylase Inhibitors and Perifosine Synergistically Induces Apoptosis in Human Leukemia Cells through Akt and ERK1/2 Inactivation and the Generation of Ceramide and Reactive Oxygen Species
Cancer Res., March 15, 2005; 65(6): 2422 - 2432.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Z. N. Demidenko and M. V. Blagosklonny
Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor
Cancer Res., May 15, 2004; 64(10): 3653 - 3660.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. C. Maggio, R. R. Rosato, L. B. Kramer, Y. Dai, M. Rahmani, D. S. Paik, A. C. Czarnik, S. G. Payne, S. Spiegel, and S. Grant
The Histone Deacetylase Inhibitor MS-275 Interacts Synergistically with Fludarabine to Induce Apoptosis in Human Leukemia Cells
Cancer Res., April 1, 2004; 64(7): 2590 - 2600.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. R. Rosato, J. A. Almenara, C. Yu, and S. Grant
Evidence of a Functional Role for p21WAF1/CIP1 Down-Regulation in Synergistic Antileukemic Interactions between the Histone Deacetylase Inhibitor Sodium Butyrate and Flavopiridol
Mol. Pharmacol., March 1, 2004; 65(3): 571 - 581.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. M. Nguyen, W. D. Schrump, G. A. Chen, W. Tsai, P. Nguyen, J. B. Trepel, and D. S. Schrump
Abrogation of p21 Expression by Flavopiridol Enhances Depsipeptide-Mediated Apoptosis in Malignant Pleural Mesothelioma Cells
Clin. Cancer Res., March 1, 2004; 10(5): 1813 - 1825.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Rahmani, C. Yu, Y. Dai, E. Reese, W. Ahmed, P. Dent, and S. Grant
Coadministration of the Heat Shock Protein 90 Antagonist 17-Allylamino- 17-demethoxygeldanamycin with Suberoylanilide Hydroxamic Acid or Sodium Butyrate Synergistically Induces Apoptosis in Human Leukemia Cells
Cancer Res., December 1, 2003; 63(23): 8420 - 8427.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
R. R. Rosato, J. A. Almenara, Y. Dai, and S. Grant
Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells
Mol. Cancer Ther., December 1, 2003; 2(12): 1273 - 1284.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. R. Rosato, J. A. Almenara, and S. Grant
The Histone Deacetylase Inhibitor MS-275 Promotes Differentiation or Apoptosis in Human Leukemia Cells through a Process Regulated by Generation of Reactive Oxygen Species and Induction of p21CIP1/WAF1 1
Cancer Res., July 1, 2003; 63(13): 3637 - 3645.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Yu, M. Rahmani, J. Almenara, M. Subler, G. Krystal, D. Conrad, L. Varticovski, P. Dent, and S. Grant
Histone Deacetylase Inhibitors Promote STI571-mediated Apoptosis in STI571-sensitive and -resistant Bcr/Abl+ Human Myeloid Leukemia Cells
Cancer Res., May 1, 2003; 63(9): 2118 - 2126.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Alonso, C. Tamasdan, D. C. Miller, and E. W. Newcomb
Flavopiridol Induces Apoptosis in Glioma Cell Lines Independent of Retinoblastoma and p53 Tumor Suppressor Pathway Alterations by a Caspase-independent Pathway
Mol. Cancer Ther., February 1, 2003; 2(2): 139 - 150.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. Cartee, S. C. Maggio, R. Smith, H. M. Sankala, P. Dent, and S. Grant
Protein Kinase C-dependent Activation of the Tumor Necrosis Factor Receptor-mediated Extrinsic Cell Death Pathway Underlies Enhanced Apoptosis in Human Myeloid Leukemia Cells Exposed to Bryostatin 1 and Flavopiridol
Mol. Cancer Ther., January 1, 2003; 2(1): 83 - 93.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.